These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32150065)

  • 21. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.
    Vinjamuri S; Gilbert TM; Banks M; McKane G; Maltby P; Poston G; Weissman H; Palmer DH; Vora J; Pritchard DM; Cuthbertson DJ
    Br J Cancer; 2013 Apr; 108(7):1440-8. PubMed ID: 23492685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis.
    Dannoon SF; Alenezi SA; Elgazzar AH
    Nucl Med Commun; 2017 Dec; 38(12):1085-1093. PubMed ID: 28957840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
    Claringbold PG; Price RA; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.
    Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R
    Clin Nucl Med; 2020 Sep; 45(9):e393-e399. PubMed ID: 32604121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
    Satapathy S; Mittal BR
    Nucl Med Commun; 2019 Dec; 40(12):1195-1203. PubMed ID: 31658219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective observational study of
    Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
    Strosberg J; Leeuwenkamp O; Siddiqui MK
    Cancer Treat Rev; 2021 Feb; 93():102141. PubMed ID: 33418096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
    Løitegård T; Berntzen DT; Thiis-Evensen E
    Ann Nucl Med; 2019 Mar; 33(3):147-152. PubMed ID: 30406360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Efficacy, Survival, and Safety of [
    Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
    Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
    [No Abstract]   [Full Text] [Related]  

  • 38.
    Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
    JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 3 Trial of
    Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
    N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.